Destiny Pharma

LN: DEST

£36.2m market cap

83p last close

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobial agents that have unique properties to improve outcomes for patients. Destiny’s first product, XF-73, is about to start a US Phase IIb clinical study.

Investment summary

Destiny has had two positive and supportive announcements. The UK government has announced a number of initiatives and strategies to significantly enhance the return on investment for companies like Destiny that are developing new drugs to combat antimicrobial resistance (AMR). In addition Destiny has been awarded a £1.6m UK-China AMR grant.

Y/E Dec
Revenue (£m)
EBITDA (£m)
PBT (£m)
EPS (fd) (p)
P/E (x)
P/CF (x)
2016A 0.0 (1.3) (1.5) (3.94) N/A N/A
2017A 0.0 (2.5) (3.2) (8.45) N/A N/A
2018E 0.0 (6.8) (7.4) (14.28) N/A N/A
2019E 0.5 (8.3) (8.3) (15.29) N/A N/A
Last updated on 15/02/2019
Industry outlook

While there are valid commercial criticisms of antibiotic development, the growing problem of antimicrobial resistance is making non-dilutive and alternative funding methods available to make antimicrobial drug development easier on companies. In addition, resistance has not been observed against Destiny’s agents and their new preventative indications make antibiotic stewardship less of an issue.

Last updated on 15/02/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (£m) 11457
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 29.7 14.5 (40.3)
Relative* 24.0 11.7 (39.9)
52-week high/low 137.0p/61.5p
*% relative to local index
Key management
Neil Clark CEO
Shaun Claydon CFO
Dr. William Love Founder and Chief Scientific Officer